Patents by Inventor Lianhai Li

Lianhai Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210127323
    Abstract: Apparatuses, methods, and systems are disclosed for determining a time-frequency resource for transmitting and/or receiving using a system parameter. One apparatus (200) includes a receiver (212) that receives (702) system information on a time-frequency resource. The time-frequency resource is determined by a system parameter, and the system parameter includes a system operation mode.
    Type: Application
    Filed: March 24, 2017
    Publication date: April 29, 2021
    Inventors: Zhi Yan, Xiaodong Yu, Haipeng Lei, Lianhai Wu, Yingying Li
  • Patent number: 10992367
    Abstract: Apparatuses, methods, and systems are disclosed for beam switching. One apparatus (200) includes a transmitter (210) that transmits (402) information indicating a beam switch request, measurement results, or some combination thereof, wherein the information indicates a list of beams, and the information is based on a trigger event, the measurement results, or some combination thereof.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: April 27, 2021
    Assignee: Motorola Mobility LLC
    Inventors: Lianhai Wu, Chenxi Zhu, Haipeng Lei, Zhuoyun Zhang, Hongchao Li
  • Patent number: 10605852
    Abstract: A concomitant impedance protection method for a half-wavelength power transmission line includes that: three-phase currents and three-phase voltages of a relay protection device mounting position at an M side and a relay protection device mounting position at an N side of the half-wavelength power transmission line are acquired respectively; it is judged whether starting amounts of an M side and an N side meet starting conditions or not; a failure point F is determined according to a time difference when the starting amounts of the M side and the N side meet the starting conditions; and a relay protection action of the half-wavelength power transmission line is started according to concomitant impedance of the half-wavelength power transmission line.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: March 31, 2020
    Assignees: CHINA ELECTRIC POWER RESEARCH INSTITUTE COMPANY LIMITED, STATE GRID CORPORATION OF CHINA, CENTRAL CHINA BRANCH OF STATE GRID CORPORATION OF CHINA
    Inventors: Dingxiang Du, Huanzhang Liu, Zexin Zhou, Xuming Liang, Yarong Guo, Xingguo Wang, Lianhai Li, Delin Wang, Xiao Li, Xiangwen Chen
  • Publication number: 20190210973
    Abstract: Provided are compounds having Formula (1), compositions thereof, and methods of modulating CFTR activity. Also provided are methods of treating a condition associated with decreased CFTR activity comprising administering to a subject an effective amount of a compound of Formula (1), optionally with other therapeutic agent(s).
    Type: Application
    Filed: January 4, 2019
    Publication date: July 11, 2019
    Inventors: Lianhai LI, Tzyh-Chang HWANG, Xiaoqin Zou
  • Publication number: 20180364292
    Abstract: A concomitant impedance protection method for a half-wavelength power transmission line includes that: three-phase currents and three-phase voltages of a relay protection device mounting position at an M side and a relay protection device mounting position at an N side of the half-wavelength power transmission line are acquired respectively; it is judged whether starting amounts of an M side and an N side meet starting conditions or not; a failure point F is determined according to a time difference when the starting amounts of the M side and the N side meet the starting conditions; and a relay protection action of the half-wavelength power transmission line is started according to concomitant impedance of the half-wavelength power transmission line.
    Type: Application
    Filed: June 30, 2016
    Publication date: December 20, 2018
    Applicants: CHINA ELECTRIC POWER RESEARCH INSTITUTE COMPANY LIMITED, STATE GRID CORPORATION OF CHINA, CENTRAL CHINA BRANCH OF STATE GRID CORPORATION OF CHINA
    Inventors: Dingxiang Du, Huanzhang Liu, Zexin Zhou, Xuming Liang, Yarong Guo, Xingguo Wang, Lianhai Li, Delin Wang, Xiao Li, Xiangwen Chen
  • Patent number: 9814719
    Abstract: The present disclosure relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present disclosure provides compounds as therapeutic agents against bacterial infections (e.g., biofilms). The present disclosure also provides compounds as therapeutic agents in methods for treating pneumonia, methods for reducing bacterial virulence, methods for treating a bacterial wound infection, and methods for treating a urinary tract infection. The present disclosure also provides methods for treating a bacterial infection, wherein the bacterial infection has or is suspected of having an antibiotic-resistant bacteria. The present disclosure also provides surfaces coated with the chemical compounds disclosed herein.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: November 14, 2017
    Assignee: Curators of the University of Missouri
    Inventors: Hongmin Sun, David W. Anderson, Lianhai Li
  • Publication number: 20170056405
    Abstract: The present disclosure relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present disclosure provides compounds as therapeutic agents against bacterial infections (e.g., biofilms). The present disclosure also provides compounds as therapeutic agents in methods for treating pneumonia, methods for reducing bacterial virulence, methods for treating a bacterial wound infection, and methods for treating a urinary tract infection. The present disclosure also provides methods for treating a bacterial infection, wherein the bacterial infection has or is suspected of having an antibiotic-resistant bacteria. The present disclosure also provides surfaces coated with the chemical compounds disclosed herein.
    Type: Application
    Filed: October 26, 2016
    Publication date: March 2, 2017
    Inventors: Hongmin Sun, David W. Anderson, Lianhai Li
  • Patent number: 9458162
    Abstract: The present document describes novel molecules having protein tyrosine kinase inhibitory activity, and methods of synthesizing and using such compounds. More specifically, the present document describes compound of Formula (A): (Formula (A)) or a pharmaceutically acceptable salt, hydrate or solvate thereof, and methods of synthesizing and using such compounds.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: October 4, 2016
    Assignee: Nanjing Allgen Pharma Co. Ltd.
    Inventors: Zhaoyin Wang, Lianhai Li, Zhigang Wang
  • Patent number: 9345905
    Abstract: The present document describes compounds of Formula I, pharmaceutical compositions comprising the same as well as methods of treating diseases such as a cancer, neurological disease, neurodegenerative disorder, stroke, traumatic brain injury, parasitic infection, inflammation or an autoimmune disease with said compounds.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: May 24, 2016
    Assignee: NANJING ALLGEN PHARMA CO. LTD.
    Inventors: Zhaoyin Wang, Lianhai Li
  • Patent number: 9226923
    Abstract: The present invention relates to spirocyclic compounds of formula I, namely spirocyclic (1H-pyrazol-4-yl)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amines having protein kinase inhibitory activity, and methods of synthesizing and using such compounds. Preferred compounds are c-Met and/or ALK inhibitors useful for the treatment of abnormal cell growth, such as cancers.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: January 5, 2016
    Assignee: Nanjing Allgen Pharma Co. Ltd.
    Inventors: Zhaoyin Wang, Lianhai Li, Zhigang Wang
  • Publication number: 20150011530
    Abstract: The present document describes novel molecules having protein tyrosine kinase inhibitory activity, and methods of synthesizing and using such compounds. More specifically, the present document describes compound of Formula (A): (Formula (A)) or a pharmaceutically acceptable salt, hydrate or solvate thereof, and methods of synthesizing and using such compounds.
    Type: Application
    Filed: January 30, 2013
    Publication date: January 8, 2015
    Inventors: Zhaoyin Wang, Lianhai Li, Zhigang Wang
  • Publication number: 20140322229
    Abstract: The present document describes compounds of Formula I, pharmaceutical compositions comprising the same as well as methods of treating diseases such as a cancer, neurological disease, neurodegenerative disorder, stroke, traumatic brain injury, parasitic infection, inflammation or an autoimmune disease with said compounds.
    Type: Application
    Filed: November 29, 2012
    Publication date: October 30, 2014
    Inventors: Zhaoyin Wang, Lianhai Li
  • Publication number: 20140243303
    Abstract: The present invention relates to spirocyclic compounds of formula I, namely spirocyclic (1H-pyrazol-4-yl)-3-(1-(2,6-dichloro-3-fiuorophenyl)ethoxy)pyridin-2-amines having protein kinase inhibitory activity, and methods of synthesizing and using such compounds. Preferred compounds are c-Met and/or ALK inhibitors useful for the treatment of abnormal cell growth, such as cancers.
    Type: Application
    Filed: July 26, 2012
    Publication date: August 28, 2014
    Applicant: Beta Pharma Canada Inc.
    Inventors: Zhaoyin Wang, Lianhai Li, Zhigang Wang
  • Publication number: 20120115921
    Abstract: Fluoro substituted cycloalkanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.
    Type: Application
    Filed: January 19, 2012
    Publication date: May 10, 2012
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Carl Berthelette, Nicolas Lachance, Lianhai Li, Claudio Sturino, Zhaoyin Wang
  • Publication number: 20110301143
    Abstract: Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R1— substituted heteroaryl, R1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N—CR5R6, C?CR5 or CR13—CR5R6, Y is a bond or —C(O)—, a and b represent an integer selected from 1 to 4, and Ar is an optionally substituted phenyl or naphtyl, are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) The heterocyclic compounds are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis, obesity, diabetes, neurological disease, Metabolic Syndrome, insulin resistance, cancer, liver steatosis, and non-alcoholic steatohepatitis.
    Type: Application
    Filed: February 18, 2010
    Publication date: December 8, 2011
    Inventors: Elise Isabel, Nicolas Lachance, Jean-Philippe Leclerc, Serge Leger, Renata M. Oballa, David Powell, Yeeman K. Ramtohul, Patrick Roy, Geoffrey K. Tranmer, Renee Aspiotis, Lianhai Li, Evelyn Martins
  • Publication number: 20100298347
    Abstract: Substituted 2-naphthoic acids of structural formula are effective as antagonists of the biological activity of GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and conditions associated with the Metabolic Syndrome.
    Type: Application
    Filed: December 1, 2008
    Publication date: November 25, 2010
    Applicant: MERCK FROSST CANADA LTD
    Inventors: Michel Belley, Denis Deschenes, Rejean Fortin, Jean-Francois Fournier, Sebastien Gagne, Yves Gareau, Jacques Yves Gauthier, Lianhai Li, Joel Robichaud, Michel Therien, Geoffrey K. Tranmer, Zhaoyin Wang
  • Publication number: 20100179173
    Abstract: Fused pyrimidine compounds of structural formula (I) are effective as antagonists of the biological activity of the GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and Metabolic Syndrome.
    Type: Application
    Filed: June 26, 2008
    Publication date: July 15, 2010
    Inventors: Daniel Guay, Christian Beaulieu, Michel Belley, Sheldon N. Crane, Jeancarlo De Luca, Rejean Fortin, Yves Gareau, Lianhai Li, Michel Therien, Geoffrey K. Tranmer, Vouy Linh Truong, Zhaoyin Wang
  • Publication number: 20100137371
    Abstract: The instant invention provides compounds of Formula (I) which are leukotriene biosynthesis inhibitors. Compounds of formula (I) are useful as anti-asthmatic, anti-allergic, anti-inflammatory, cytoprotective and anti-artherosclerotic agents.
    Type: Application
    Filed: August 8, 2006
    Publication date: June 3, 2010
    Inventors: Carl Berthelette, Claude Dufresne, Lianhai Li, zhaoyin Wang
  • Publication number: 20100081696
    Abstract: Fluoro substituted cycloalkanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.
    Type: Application
    Filed: September 30, 2009
    Publication date: April 1, 2010
    Inventors: Carl Berthelette, Nicolas Lachance, Lianhai Li, Claudio Sturino, Zhaoyin Wang
  • Patent number: 7622502
    Abstract: The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events.
    Type: Grant
    Filed: January 25, 2005
    Date of Patent: November 24, 2009
    Assignee: Merck Frosst Canada & Co.
    Inventors: Carl Berthelette, Lianhai Li, Christian Beaulieu, Zhaoyin Wang, Claudio F. Sturino